Is GNLX or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Lisata Therapeutics N/A -103.54% -83.08%

Is LSTA or CGTX more profitable?

Cognition Therapeutics' return on equity of -72.68% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Cognition Therapeutics N/A -72.68% -53.07%

Do analysts recommend LSTA or THAR?

Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 331.03%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LSTA or THAR more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Tharimmune N/A -588.45% -264.41%

Do analysts rate SPRO or LSTA?

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 331.03%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is LSTA or CRDL more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Cardiol Therapeutics N/A -229.43% -165.60%

Lisata Therapeutics (LSTA) Competitors

$3.51 -0.01 (-0.40%)

As of 03:39 PM Eastern

Compare

LSTA vs. GNLX, CGTX, THAR, SPRO, and CRDL

Should you buy Lisata Therapeutics stock or one of its competitors? MarketBeat compares Lisata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lisata Therapeutics include Genelux (GNLX), Cognition Therapeutics (CGTX), Tharimmune (THAR), Spero Therapeutics (SPRO), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does Lisata Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Lisata Therapeutics has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,165.02	-$32.15M	-$0.85	N/A
Lisata Therapeutics	$170K	186.49	-$16.59M	-$1.86	N/A

In the previous week, Lisata Therapeutics' average media sentiment score of 0.90 beat Genelux's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
Lisata Therapeutics	Positive

Genelux has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 513.08%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 331.03%. Given Genelux's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genelux is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

37.3% of Genelux shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lisata Therapeutics' return on equity of -103.54% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Summary

Lisata Therapeutics beats Genelux on 8 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Cognition Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Lisata Therapeutics has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	186.49	-$16.59M	-$1.86	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Cognition Therapeutics' return on equity of -72.68% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cognition Therapeutics had 3 more articles in the media than Lisata Therapeutics. MarketBeat recorded 3 mentions for Cognition Therapeutics and 0 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.90 beat Cognition Therapeutics' score of 0.67 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Positive
Cognition Therapeutics	Positive

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 331.03%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 101.41%. Given Lisata Therapeutics' higher possible upside, research analysts plainly believe Lisata Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats Lisata Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Tharimmune?

Lisata Therapeutics (NASDAQ:LSTA) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 331.03%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lisata Therapeutics' average media sentiment score of 0.90 beat Tharimmune's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Positive
Tharimmune	Neutral

Lisata Therapeutics' return on equity of -103.54% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Tharimmune	N/A	-588.45%	-264.41%

Lisata Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Tharimmune has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	186.49	-$16.59M	-$1.86	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by insiders. Comparatively, 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lisata Therapeutics beats Tharimmune on 9 of the 12 factors compared between the two stocks.

How does Lisata Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Spero Therapeutics had 4 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Spero Therapeutics and 0 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.90 beat Spero Therapeutics' score of 0.56 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Spero Therapeutics	Positive
Lisata Therapeutics	Positive

Spero Therapeutics has a net margin of 24.90% compared to Lisata Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Lisata Therapeutics	N/A	-103.54%	-83.08%

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spero Therapeutics has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.90	$8.57M	$0.24	9.15
Lisata Therapeutics	$170K	186.49	-$16.59M	-$1.86	N/A

Spero Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 331.03%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Spero Therapeutics beats Lisata Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Cardiol Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Lisata Therapeutics' return on equity of -103.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 331.03%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 698.12%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lisata Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	186.49	-$16.59M	-$1.86	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lisata Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

In the previous week, Lisata Therapeutics' average media sentiment score of 0.90 beat Cardiol Therapeutics' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Positive
Cardiol Therapeutics	Neutral

Summary

Lisata Therapeutics beats Cardiol Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.70M	$3.45B	$6.44B	$12.40B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-1.87	20.02	24.86	24.31
Price / Sales	186.49	332.39	573.97	130.40
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	2.10	8.37	10.87	6.60
Net Income	-$16.59M	$23.86M	$3.56B	$336.86M
7 Day Performance	0.87%	3.87%	0.96%	-0.31%
1 Month Performance	10.83%	1.98%	0.53%	1.70%
1 Year Performance	40.32%	58.84%	30.98%	33.97%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	2.5713 of 5 stars	$3.51 -0.4%	$15.00 +327.8%	+41.9%	$31.94M	$170K	N/A	30
GNLX Genelux	1.4373 of 5 stars	$2.85 -5.9%	$18.00 +531.6%	-0.3%	$127.79M	$10K	N/A	10	Positive News High Trading Volume
CGTX Cognition Therapeutics	4.172 of 5 stars	$1.42 +12.7%	$3.33 +134.7%	+468.6%	$127.09M	N/A	N/A	20	Analyst Forecast High Trading Volume
THAR Tharimmune	N/A	$3.30 +2.8%	N/A	+150.0%	$124.51M	N/A	N/A	2
SPRO Spero Therapeutics	1.4238 of 5 stars	$2.11 -23.8%	N/A	-24.5%	$122.17M	$54.77M	8.79	150	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. GNLX, CGTX, THAR, SPRO, and CRDL

How does Lisata Therapeutics compare to Genelux?

Summary

How does Lisata Therapeutics compare to Cognition Therapeutics?

Summary

How does Lisata Therapeutics compare to Tharimmune?

Summary

How does Lisata Therapeutics compare to Spero Therapeutics?

Summary

How does Lisata Therapeutics compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. GNLX, CGTX, THAR, SPRO, and CRDL

How does Lisata Therapeutics compare to Genelux?

Which has better valuation and earnings, GNLX or LSTA?

Does the media refer more to GNLX or LSTA?

Which has more volatility & risk, GNLX or LSTA?

Do analysts rate GNLX or LSTA?

Do insiders and institutionals believe in GNLX or LSTA?

Is GNLX or LSTA more profitable?

Summary

How does Lisata Therapeutics compare to Cognition Therapeutics?

Which has better valuation and earnings, LSTA or CGTX?

Is LSTA or CGTX more profitable?

Which has more volatility & risk, LSTA or CGTX?

Do insiders and institutionals have more ownership in LSTA or CGTX?

Does the media prefer LSTA or CGTX?

Do analysts rate LSTA or CGTX?

Summary

How does Lisata Therapeutics compare to Tharimmune?

Do analysts recommend LSTA or THAR?

Does the media refer more to LSTA or THAR?

Is LSTA or THAR more profitable?

Which has more volatility and risk, LSTA or THAR?

Which has stronger earnings & valuation, LSTA or THAR?

Do institutionals and insiders have more ownership in LSTA or THAR?

Summary

How does Lisata Therapeutics compare to Spero Therapeutics?

Does the media favor SPRO or LSTA?

Is SPRO or LSTA more profitable?

Do institutionals & insiders have more ownership in SPRO or LSTA?

Which has better valuation and earnings, SPRO or LSTA?

Which has more volatility & risk, SPRO or LSTA?

Do analysts rate SPRO or LSTA?

Summary

How does Lisata Therapeutics compare to Cardiol Therapeutics?

Is LSTA or CRDL more profitable?

Do analysts recommend LSTA or CRDL?

Which has preferable earnings and valuation, LSTA or CRDL?

Do insiders and institutionals have more ownership in LSTA or CRDL?

Which has more risk & volatility, LSTA or CRDL?

Does the media favor LSTA or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools